CA1223201A - Process for the preparation of the c1 inactivator and its use - Google Patents

Process for the preparation of the c1 inactivator and its use

Info

Publication number
CA1223201A
CA1223201A CA000433647A CA433647A CA1223201A CA 1223201 A CA1223201 A CA 1223201A CA 000433647 A CA000433647 A CA 000433647A CA 433647 A CA433647 A CA 433647A CA 1223201 A CA1223201 A CA 1223201A
Authority
CA
Canada
Prior art keywords
inactivator
purified
hepatitis
solution
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000433647A
Other languages
English (en)
French (fr)
Inventor
Hermann Pelzer
Helmut Heber
Norbert Heimburger
Hans M. Preis
Horst Naumann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
CSL Behring GmbH Deutschland
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to CA000511888A priority Critical patent/CA1236015A/en
Application granted granted Critical
Publication of CA1223201A publication Critical patent/CA1223201A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/005—Stabilisers against oxidation, heat, light, ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA000433647A 1982-07-30 1983-07-29 Process for the preparation of the c1 inactivator and its use Expired CA1223201A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000511888A CA1236015A (en) 1982-07-30 1986-06-18 Process for the preparation of the c1 inactivator and its use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19823228502 DE3228502A1 (de) 1982-07-30 1982-07-30 Verfahren zur herstellung des c1-inaktivators und seine verwendung
DEP3228502.7 1982-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA000511888A Division CA1236015A (en) 1982-07-30 1986-06-18 Process for the preparation of the c1 inactivator and its use

Publications (1)

Publication Number Publication Date
CA1223201A true CA1223201A (en) 1987-06-23

Family

ID=6169724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000433647A Expired CA1223201A (en) 1982-07-30 1983-07-29 Process for the preparation of the c1 inactivator and its use

Country Status (9)

Country Link
US (1) US4915945A (enExample)
EP (1) EP0101935B1 (enExample)
JP (2) JPS5944320A (enExample)
AT (1) ATE19590T1 (enExample)
AU (1) AU564614B2 (enExample)
CA (1) CA1223201A (enExample)
DE (2) DE3228502A1 (enExample)
ES (2) ES524511A0 (enExample)
ZA (1) ZA835561B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376367B (de) * 1983-03-16 1984-11-12 Immuno Ag Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten
JPH0742235B2 (ja) * 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
FR2618784B1 (fr) * 1987-07-30 1990-04-06 Lille Transfusion Sanguine Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
JP2729484B2 (ja) * 1988-04-28 1998-03-18 株式会社ミドリ十字 アンチトロンビン−▲ｉｉｉ▼の精製方法
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5622930A (en) * 1989-10-27 1997-04-22 Clb C1 inhibitor muteins and uses thereof
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) * 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
DE69429816T2 (de) * 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU6083899A (en) 1999-09-16 2001-04-17 Aventis Behring Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
AU2012311483B2 (en) 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
CN104080474B (zh) 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
JP2017501968A (ja) 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
US10532087B2 (en) 2015-06-03 2020-01-14 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja) 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
BR112019023737A2 (pt) 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CA3075686A1 (en) 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
EP3867262A1 (en) * 2018-10-17 2021-08-25 CSL Behring GmbH Process for purifying c1-inh
KR20220029732A (ko) 2019-07-04 2022-03-08 체에스엘 베링 게엠베하 C1-inh를 정제하는 방법
RU2769201C2 (ru) * 2020-06-23 2022-03-29 Акционерное общество "ГЕНЕРИУМ" Способ получения высокоочищенного рекомбинантного ингибитора с1-эстеразы человека для медицинского применения
CN116568327A (zh) 2020-11-20 2023-08-08 德国杰特贝林生物制品有限公司 治疗抗体介导的排斥反应的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322139B2 (enExample) * 1973-11-15 1978-07-06
NL7602846A (nl) * 1976-03-18 1977-09-20 Leuven Res & Dev Vzw Antiplasmine en een antiserum daartegen.
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
EP0035204B2 (en) * 1980-03-05 1991-05-22 Miles Inc. Pasteurized therapeutically active protein compositions
JPS56154419A (en) * 1980-04-30 1981-11-30 Green Cross Corp:The Heat treatment of alpha-fetoprotein-containing aqueous solution

Also Published As

Publication number Publication date
EP0101935A1 (de) 1984-03-07
ES8404372A1 (es) 1984-04-16
ES524511A0 (es) 1984-04-16
DE3363395D1 (en) 1986-06-12
US4915945A (en) 1990-04-10
ES525361A0 (es) 1984-11-16
ES8501413A1 (es) 1984-11-16
JPS5944320A (ja) 1984-03-12
AU1745183A (en) 1984-02-02
DE3228502A1 (de) 1984-02-02
JPH07103044B2 (ja) 1995-11-08
AU564614B2 (en) 1987-08-20
ATE19590T1 (de) 1986-05-15
ZA835561B (en) 1984-03-28
JPH0480886B2 (enExample) 1992-12-21
JPH05306236A (ja) 1993-11-19
EP0101935B1 (de) 1986-05-07

Similar Documents

Publication Publication Date Title
US4915945A (en) Process for the preparation of the C1 inactivator
US4340589A (en) Antithrombin preparation and process for the production thereof
EP0037078B1 (en) Process for heat treatment of aqueous solution containing human blood coagulation factor xiii
KR870002161B1 (ko) 비루스 왁진의 제조방법
US4251510A (en) Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
CA1183084A (en) Intravenously injectable immune serum globulin
EP0374625B1 (en) Viral inactivation process
US4424206A (en) Process for heat treatment of aqueous solution containing cold insoluble globulin to inactivate hepatitis virus
US4378346A (en) Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
FI60501B (fi) Foerfarande foer selektiv separering av interferon fraon interferon-raopreparat
NZ241701A (en) Preparation of standardised, purified von willebrand factor by treatment of cryoprecipitated fraction of plasma with two ion exchange treatments and an affinity chromatography treatment
EP0140386B1 (en) Method for the purification of lpf-ha
JPS62138434A (ja) アルフア−１−プロテイナ−ゼ阻害剤の製造法
Hoffman Purification and large-scale preparation of antithrombin III
AU622102B2 (en) A pharmaceutical containing tissue protein pp4, a process for the preparation of pp4 and for the pasteurization thereof, and the use of pp4
WO1984003628A1 (en) A concentrate of the antihemophilic factor viii and a process for producing it
EP0011739B1 (en) Process for obtaining blood coagulation factor xiii derived from human placenta
US4822872A (en) Method of purifying factor VIII
JPS61189228A (ja) 血液凝固第８因子製剤の製法
JPS6159610B2 (enExample)
CA1236015A (en) Process for the preparation of the c1 inactivator and its use
EP0449897B1 (en) A pure factor i protein and a process for producing said protein
JPS62292731A (ja) 低温殺菌された免疫グロブリン製剤の製法
JPS6140392B2 (enExample)
CA1307373C (en) Process for the isolation and preparation of a pasteurized alpha_-antiplasmin product

Legal Events

Date Code Title Description
MKEX Expiry